Contact

All Stories

  1. Supplementary Figure 1 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • June 2026, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  2. Supplementary Figure 10 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • June 2026, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  3. Supplementary Figure 11 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • June 2026, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  4. Supplementary Figure 12 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • June 2026, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  5. Supplementary Figure 13 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • June 2026, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  6. Supplementary Figure 14 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • June 2026, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  7. Supplementary Figure 15 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • June 2026, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  8. Supplementary Figure 16 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • June 2026, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  9. Supplementary Figure 17 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • June 2026, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  10. Supplementary Figure 18 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • June 2026, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  11. Supplementary Figure 2 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • June 2026, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  12. Supplementary Figure 3 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • June 2026, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  13. Supplementary Figure 4 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • June 2026, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  14. Supplementary Figure 5 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • June 2026, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  15. Supplementary Figure 6 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • June 2026, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  16. Supplementary Figure 7 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • June 2026, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  17. Supplementary Figure 8 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • June 2026, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  18. Supplementary Figure 9 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • June 2026, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  19. Supplementary Table 1 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • June 2026, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  20. Supplementary Table 2 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • June 2026, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  21. Supplementary Table 3 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • June 2026, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  22. Varied Presentations of Arterial Events in Vascular Ehlers-Danlos Syndrome

    Article • JACC Case Reports, September 2025, Elsevier

    Dr. Louis Maximilian Buja

  23. Insights from autopsy-initiated pathological studies of the pathogenesis and clinical manifestations of atherosclerosis and ischemic heart disease: Part I. Atherosclerosis

    Article • Cardiovascular Pathology, May 2025, Elsevier

    Dr. Louis Maximilian Buja

  24. Insights from autopsy-initiated pathological studies of the pathogenesis and clinical manifestations of atherosclerosis and ischemic heart disease: Part II. Ischemic heart disease

    Article • Cardiovascular Pathology, May 2025, Elsevier

    Dr. Louis Maximilian Buja

  25. Pathobiology of Aortic Aneurysms and Dissections

    Article • JACC Advances, May 2025, Elsevier

    Dr. Louis Maximilian Buja

  26. Histology-Grounded Automated Plaque Subtype Segmentation in Intravascular Optical Coherence Tomography

    Article • Journal of the Society for Cardiovascular Angiography & Interventions, March 2025, Elsevier

    Dr. Louis Maximilian Buja

  27. Data from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  28. Supplementary Figure 1 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  29. Supplementary Figure 1 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  30. Supplementary Figure 10 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  31. Supplementary Figure 10 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  32. Supplementary Figure 11 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  33. Supplementary Figure 11 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  34. Supplementary Figure 12 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  35. Supplementary Figure 12 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  36. Supplementary Figure 13 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  37. Supplementary Figure 13 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  38. Supplementary Figure 14 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  39. Supplementary Figure 14 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  40. Supplementary Figure 15 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  41. Supplementary Figure 15 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  42. Supplementary Figure 16 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  43. Supplementary Figure 16 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  44. Supplementary Figure 17 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  45. Supplementary Figure 17 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  46. Supplementary Figure 18 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  47. Supplementary Figure 18 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  48. Supplementary Figure 2 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  49. Supplementary Figure 2 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  50. Supplementary Figure 3 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  51. Supplementary Figure 3 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  52. Supplementary Figure 4 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  53. Supplementary Figure 4 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  54. Supplementary Figure 5 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  55. Supplementary Figure 5 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  56. Supplementary Figure 6 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  57. Supplementary Figure 6 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  58. Supplementary Figure 7 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  59. Supplementary Figure 7 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  60. Supplementary Figure 8 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  61. Supplementary Figure 8 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  62. Supplementary Figure 9 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  63. Supplementary Figure 9 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  64. Supplementary Table 1 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  65. Supplementary Table 1 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  66. Supplementary Table 2 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  67. Supplementary Table 2 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  68. Supplementary Table 3 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  69. Supplementary Table 3 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  70. Data from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  71. Supplementary Figure 1 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  72. Supplementary Figure 1 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  73. Supplementary Figure 10 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  74. Supplementary Figure 10 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  75. Supplementary Figure 11 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  76. Supplementary Figure 11 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  77. Supplementary Figure 12 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  78. Supplementary Figure 12 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  79. Supplementary Figure 13 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  80. Supplementary Figure 13 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  81. Supplementary Figure 14 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  82. Supplementary Figure 14 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  83. Supplementary Figure 15 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  84. Supplementary Figure 15 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  85. Supplementary Figure 16 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  86. Supplementary Figure 16 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  87. Supplementary Figure 17 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  88. Supplementary Figure 17 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  89. Supplementary Figure 18 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  90. Supplementary Figure 18 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  91. Supplementary Figure 2 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  92. Supplementary Figure 2 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  93. Supplementary Figure 3 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  94. Supplementary Figure 3 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  95. Supplementary Figure 4 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  96. Supplementary Figure 4 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  97. Supplementary Figure 5 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  98. Supplementary Figure 5 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  99. Supplementary Figure 6 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  100. Supplementary Figure 6 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  101. Supplementary Figure 7 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  102. Supplementary Figure 7 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  103. Supplementary Figure 8 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  104. Supplementary Figure 8 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  105. Supplementary Figure 9 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  106. Supplementary Figure 9 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  107. Supplementary Table 1 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  108. Supplementary Table 1 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  109. Supplementary Table 2 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  110. Supplementary Table 2 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  111. Supplementary Table 3 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  112. Supplementary Table 3 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • August 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  113. Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis

    Article • Cancer Immunology Research, May 2024, American Association for Cancer Research (AACR)

    Dr. Louis Maximilian Buja

  114. Pericentrin deficiency in smooth muscle cells augments atherosclerosis through HSF1-driven cholesterol biosynthesis and PERK activation

    Article • JCI Insight, November 2023, American Society for Clinical Investigation

    Dr. Louis Maximilian Buja

  115. In memoriam William Clifford Roberts, MD (September 11, 1932 June 15, 2023)

    Article • Cardiovascular Pathology, November 2023, Elsevier

    Dr. Louis Maximilian Buja

  116. Environmental oxygen affects ex vivo growth and proliferation of mesenchymal progenitors by modulating mitogen-activated protein kinase and mammalian target of rapamycin signaling

    Article • Cytotherapy, December 2022, Elsevier

    Dr. Louis Maximilian Buja

  117. The history, science, and art of wine and the case for health benefits: perspectives of an oenophilic cardiovascular pathologist

    Article • Cardiovascular Pathology, September 2022, Elsevier

    Dr. Louis Maximilian Buja

  118. Hypertrophic cardiomyopathy with a complex clinical course leading to heart transplantation

    Article • Cardiovascular Pathology, May 2022, Elsevier

    Dr. Louis Maximilian Buja

  119. A novel coronavirus meets the cardiovascular system: Society for Cardiovascular Pathology Symposium 2021

    Article • Cardiovascular Pathology, July 2021, Elsevier

    Dr. Louis Maximilian Buja

  120. Commentary on the spectrum of cardiopulmonary pathology in COVID-19

    Article • Cardiovascular Pathology, July 2021, Elsevier

    Dr. Louis Maximilian Buja

  121. Electron microscopic identification of SARS-CoV-2

    Article • Cardiovascular Pathology, May 2021, Elsevier

    Dr. Louis Maximilian Buja

  122. An unexpected paradox: wall shear stress in the aorta is less in patients with severe atherosclerosis regardless of obesity

    Article • Cardiovascular Pathology, March 2021, Elsevier

    Dr. Louis Maximilian Buja

  123. EMERGING SPECTRUM OF CARDIOPULMONARY PATHOLOGY OF THE CORONAVIRUS DISEASE 2019 (COVID-19): REPORT OF THREE AUTOPSIES FROM HOUSTON, TEXAS AND REVIEW OF AUTOPSY FINDINGS FROM OTHER UNITED STATES CITIES

    Article • Cardiovascular Pathology, May 2020, Elsevier

    Dr. Louis Maximilian Buja

  124. Prevention of Heart Failure with Preserved Ejection Fraction (HFpEF): Reexamining MicroRNA-21 Inhibition in the Era of Oligonucleotide-Based Therapeutics

    Article • Cardiovascular Pathology, May 2020, Elsevier

    Dr. Louis Maximilian Buja

  125. Medical education today: all that glitters is not gold

    Article • BMC Medical Education, April 2019, Springer Science + Business Media

    Dr. Louis Maximilian Buja

  126. A case of Brucella aortitis associated with development of thoracic aortic aneurysm and aortobronchial fistula

    Article • Cardiovascular Pathology, March 2019, Elsevier

    Dr. Louis Maximilian Buja

  127. Cardiac repair and the putative role of stem cells

    Article • Journal of Molecular and Cellular Cardiology, March 2019, Elsevier

    Dr. Louis Maximilian Buja

  128. Continuing Importance of the Autopsy in Medicine

    Article • Academic Pathology, January 2019, SAGE Publications

    Dr. Louis Maximilian Buja

  129. Pathobiology of Ischemic Heart Disease: Past, Present and Future

    Article • Cardiovascular Pathology, May 2016, Elsevier

    Dr. Louis Maximilian Buja

  130. Consensus statement on surgical pathology of the aorta from the Society for Cardiovascular Pathology and the Association for European Cardiovascular Pathology: I. Inflammatory diseases

    Article • Cardiovascular Pathology, September 2015, Elsevier

    Dr. Louis Maximilian Buja

  131. Method for sectioning and sampling hearts for histologic evaluation after delivery of biological agents by transendocardial injection

    Article • Cardiovascular Pathology, September 2015, Elsevier

    Dr. Louis Maximilian Buja

  132. Procainamide-induced pulmonary fibrosis after orthotopic heart transplantation: a case report and literature review

    Article • Cardiovascular Pathology, July 2015, Elsevier

    Dr. Louis Maximilian Buja

  133. In Reply

    Article • Archives of Pathology & Laboratory Medicine, May 2015, Archives of Pathology and Laboratory Medicine

    Dr. Louis Maximilian Buja

  134. Anthracycline Treatment and Ventricular Remodeling in Left Ventricular Assist Device Patients

    Article • Texas Heart Institute Journal, April 2015, Texas Heart Institute Journal

    Dr. Louis Maximilian Buja

  135. Macrophages and Intravascular OCT Bright Spots

    Article • JACC Cardiovascular Imaging, January 2015, Elsevier

    Dr. Louis Maximilian Buja

  136. Sudden death in a 15-year-old with diffuse cardiac rhabdomyomatosis: an autopsy case report

    Article • Cardiovascular Pathology, November 2014, Elsevier

    Dr. Louis Maximilian Buja

  137. Heart Failure in Remission for More than 13 Years after Removal of a Left Ventricular Assist Device

    Article • Texas Heart Institute Journal, August 2014, Texas Heart Institute Journal

    Dr. Louis Maximilian Buja

  138. Sudden Cardiac Death Due to Coronary Artery Involvement by IgG4-Related Disease: A Rare, Serious Complication of a Rare Disease

    Article • Archives of Pathology & Laboratory Medicine, June 2014, Archives of Pathology and Laboratory Medicine

    Dr. Louis Maximilian Buja

  139. Nikolai N. Anitschkow and the lipid hypothesis of atherosclerosis

    Article • Cardiovascular Pathology, May 2014, Elsevier

    Dr. Louis Maximilian Buja

  140. Variability in fibrosis in tissue samples obtained during diaphragmatic and apical LVAD implantation

    Article • Cardiovascular Pathology, May 2014, Elsevier

    Dr. Louis Maximilian Buja

  141. HHV-6 and HHV-7 in Cardiovascular Diseases and Cardiomyopathies

    Article • January 2014, Elsevier

    Dr. Louis Maximilian Buja

  142. Granulomatous myocarditis in severe heart failure patients undergoing implantation of a left ventricular assist device

    Article • Cardiovascular Pathology, January 2014, Elsevier

    Dr. Louis Maximilian Buja

  143. Acute aortic dissections with pregnancy in women withACTA2mutations

    Article • American Journal of Medical Genetics Part A, November 2013, Wiley

    Dr. Louis Maximilian Buja

  144. Morphologic changes in the aortic wall media after support with a continuous-flow left ventricular assist device

    Article • The Journal of Heart and Lung Transplantation, November 2013, Elsevier

    Dr. Louis Maximilian Buja

  145. Aortic intimal sarcoma: report of two cases with immunohistochemical analysis for pathogenesis

    Article • Cardiovascular Pathology, September 2013, Elsevier

    Dr. Louis Maximilian Buja

  146. Fatal Cardiac and Renal Allograft Rejection With Lenalidomide Therapy for Light-Chain Amyloidosis

    Article • Arabian archaeology and epigraphy, August 2013, Wiley

    Dr. Louis Maximilian Buja

  147. Xenotransplantation of human unrestricted somatic stem cells in a pig model of acute myocardial infarction

    Article • Xenotransplantation, March 2013, Wiley

    Dr. Louis Maximilian Buja

  148. A model for cardiomyocyte cell death: Insights into mechanisms of oncosis

    Article • Experimental and Molecular Pathology, February 2013, Elsevier

    Dr. Louis Maximilian Buja

  149. A university system's approach to enhancing the educational mission of health science schools and institutions: the University of Texas Academy of Health Science Education

    Article • Medical Education Online, January 2013, Taylor & Francis

    Dr. Louis Maximilian Buja

  150. Oncosis: An important non-apoptotic mode of cell death

    Article • Experimental and Molecular Pathology, December 2012, Elsevier

    Dr. Louis Maximilian Buja

  151. Fibrosis and heart failure

    Article • Heart Failure Reviews, November 2012, Springer Science + Business Media

    Dr. Louis Maximilian Buja

  152. A pilot study of a triple antimicrobial-bonded Dacron graft for the prevention of aortic graft infection

    Article • Journal of Vascular Surgery, September 2012, Elsevier

    Dr. Louis Maximilian Buja

  153. Flat-panel versus 64-channel computed tomography for in vivo quantitative characterization of aortic atherosclerotic plaques

    Article • International Journal of Cardiology, May 2012, Elsevier

    Dr. Louis Maximilian Buja

  154. Sudden unexpected death on fingolimod

    Article • Multiple Sclerosis Journal, February 2012, SAGE Publications

    Dr. Louis Maximilian Buja

  155. Looking forward for Cardiovascular Pathology

    Article • Cardiovascular Pathology, January 2012, Elsevier

    Dr. Louis Maximilian Buja

  156. Body Temperature Circadian Rhythm Variability Corresponds to Left Ventricular Systolic Dysfunction in Decompensated Cardiomyopathic Hamsters

    Article • Journal of Cardiac Failure, November 2011, Elsevier

    Dr. Louis Maximilian Buja

  157. Current status of the role of stem cells in myocardial biology and repair

    Article • Cardiovascular Pathology, September 2011, Elsevier

    Dr. Louis Maximilian Buja

  158. Endomyocardial nodular calcification as a cause of heart failure

    Article • Cardiovascular Pathology, September 2011, Elsevier

    Dr. Louis Maximilian Buja

  159. Primary Breast Lymphoma With Sudden Death

    Article • American Journal of Forensic Medicine & Pathology, June 2011, Wolters Kluwer Health

    Dr. Louis Maximilian Buja

  160. Histopathologic correlates of myocardial improvement in patients supported by a left ventricular assist device

    Article • Cardiovascular Pathology, May 2011, Elsevier

    Dr. Louis Maximilian Buja

  161. Vascular Responses to Percutaneous Coronary Intervention With Bare-Metal Stents and Drug-Eluting Stents

    Article • Journal of the American College of Cardiology, March 2011, Elsevier

    Dr. Louis Maximilian Buja

  162. Immunologic and Inflammatory Reactions to Exogenous Stem Cells

    Article • Journal of the American College of Cardiology, November 2010, Elsevier

    Dr. Louis Maximilian Buja

  163. De novo ACTA2 mutation causes a novel syndrome of multisystemic smooth muscle dysfunction

    Article • American Journal of Medical Genetics Part A, August 2010, Wiley

    Dr. Louis Maximilian Buja

  164. Quo Vadis? The Society for Cardiovascular Pathology over the next 25 years and beyond

    Article • Cardiovascular Pathology, July 2010, Elsevier

    Dr. Louis Maximilian Buja

  165. AECVP and SCVP 2009 Recommendations for Training in Cardiovascular Pathology

    Article • Cardiovascular Pathology, May 2010, Elsevier

    Dr. Louis Maximilian Buja

  166. Cardiomyocyte PDGFR-β signaling is an essential component of the mouse cardiac response to load-induced stress

    Article • Journal of Clinical Investigation, February 2010, American Society for Clinical Investigation

    Dr. Louis Maximilian Buja

  167. Sickle Cell Trait and Fatal Rhabdomyolysis in Football Training

    Article • Medicine & Science in Sports & Exercise, January 2010, Wolters Kluwer Health

    Dr. Louis Maximilian Buja

  168. Unresolved issues in myocardial reperfusion injury

    Article • Cardiovascular Pathology, January 2010, Elsevier

    Dr. Louis Maximilian Buja

  169. Floating, Non-Occlusive, Mobile Aortic Thrombus and Splenic Infarction Associated With Protein C Deficiency

    Article • Journal of the American Society of Echocardiography, December 2009, Elsevier

    Dr. Louis Maximilian Buja

  170. Basil RuDusky: Forensic cardiovascular medicine

    Article • Forensic Science Medicine and Pathology, November 2009, Springer Science + Business Media

    Dr. Louis Maximilian Buja

  171. Evaluation of Recombinant α-Galactosidase A Therapy for Amelioration of the Cardiovascular Manifestations of Fabry Disease

    Article • Circulation, May 2009, Wolters Kluwer Health

    Dr. Louis Maximilian Buja

  172. Mutations in Smooth Muscle Alpha-Actin (ACTA2) Cause Coronary Artery Disease, Stroke, and Moyamoya Disease, Along with Thoracic Aortic Disease

    Article • The American Journal of Human Genetics, May 2009, Elsevier

    Dr. Louis Maximilian Buja

  173. The Impact of Declining Clinical Autopsy: Need for Revised Healthcare Policy

    Article • The American Journal of the Medical Sciences, January 2009, Elsevier

    Dr. Louis Maximilian Buja

  174. Histopathological Study of Healing After Allogenic Mesenchymal Stem Cell Delivery in Myocardial Infarction in Dogs

    Article • Journal of Histochemistry & Cytochemistry, November 2008, SAGE Publications

    Dr. Louis Maximilian Buja

  175. Cardiomyocyte death and renewal in the normal and diseased heart

    Article • Cardiovascular Pathology, November 2008, Elsevier

    Dr. Louis Maximilian Buja

  176. Characterization of the inflammatory cells in ascending thoracic aortic aneurysms in patients with Marfan syndrome, familial thoracic aortic aneurysms, and sporadic aneurysms

    Article • Journal of Thoracic and Cardiovascular Surgery, October 2008, Elsevier

    Dr. Louis Maximilian Buja

  177. Biatrial Myxoma: A Case Report and Review of the Literature

    Article • Journal of Cardiac Surgery, July 2008, Wiley

    Dr. Louis Maximilian Buja

  178. Location and Density of α- and β-Adrenoreceptor Sub-types in Myocardium After Mechanical Left Ventricular Unloading

    Article • The Journal of Heart and Lung Transplantation, July 2008, Elsevier

    Dr. Louis Maximilian Buja

  179. Cardiovascular distribution of the calcium sensing receptor before and after burns

    Article • Burns, May 2008, Elsevier

    Dr. Louis Maximilian Buja

  180. Comparison of intracoronary and transendocardial delivery of allogeneic mesenchymal cells in a canine model of acute myocardial infarction

    Article • Journal of Molecular and Cellular Cardiology, March 2008, Elsevier

    Dr. Louis Maximilian Buja

  181. Erratum: Corrigendum: Mutations in smooth muscle α-actin (ACTA2) lead to thoracic aortic aneurysms and dissections

    Article • Nature Genetics, February 2008, Springer Science + Business Media

    Dr. Louis Maximilian Buja

  182. Stimulation of mitochondrial biogenesis and autophagy by lipopolysaccharide in the neonatal rat cardiomyocyte protects against programmed cell death

    Article • Journal of Molecular and Cellular Cardiology, February 2008, Elsevier

    Dr. Louis Maximilian Buja

  183. Quest for the cardiovascular holy grail: mammalian myocardial regeneration

    Article • Cardiovascular Pathology, January 2008, Elsevier

    Dr. Louis Maximilian Buja

  184. Mutations in smooth muscle α-actin (ACTA2) lead to thoracic aortic aneurysms and dissections

    Article • Nature Genetics, November 2007, Springer Science + Business Media

    Dr. Louis Maximilian Buja

  185. MYH11 mutations result in a distinct vascular pathology driven by insulin-like growth factor 1 and angiotensin II

    Article • Human Molecular Genetics, April 2007, Oxford University Press (OUP)

    Dr. Louis Maximilian Buja, allan brasier

  186. Aurintricarboxylic Acid Inhibits Protein Synthesis Independent, Sanguinarine-Induced Apoptosis and Oncosis

    Article • Toxicologic Pathology, February 2007, SAGE Publications

    Dr. Louis Maximilian Buja

  187. Localization of antimicrobial peptides in normal and burned skin

    Article • Burns, June 2006, Elsevier

    Dr. Louis Maximilian Buja

  188. THE RESPONSE OF NEONATAL RAT VENTRICULAR MYOCYTES TO LIPOPOLYSACCHARIDE-INDUCED STRESS

    Article • Shock, May 2006, Wolters Kluwer Health

    Dr. Louis Maximilian Buja

  189. Transverse Aortic Arch Replacement Associated with MAGIC Syndrome: Case Report and Literature Review

    Article • Annals of Vascular Surgery, May 2006, Elsevier

    Dr. Louis Maximilian Buja

  190. Characterization of the inflammatory and apoptotic cells in the aortas of patients with ascending thoracic aortic aneurysms and dissections

    Article • Journal of Thoracic and Cardiovascular Surgery, March 2006, Elsevier

    Dr. Louis Maximilian Buja

  191. Stem cells and cardiovascular tissue repair: Mechanism, methods, and clinical applications

    Article • Journal of Cardiothoracic-Renal Research, March 2006, Elsevier

    Dr. Louis Maximilian Buja

  192. HHV-6 in Cardiovascular Pathology

    Article • January 2006, Elsevier

    Dr. Louis Maximilian Buja

  193. Toward a cardiovascular pathology training

    Article • Cardiovascular Pathology, November 2005, Elsevier

    Dr. Louis Maximilian Buja

  194. Primary Lymphoma of the Aorta Presenting as a Descending Thoracic Aortic Aneurysm

    Article • The Annals of Thoracic Surgery, October 2005, Elsevier

    Dr. Louis Maximilian Buja

  195. Left Ventricular Unloading with an Assist Device Results in Receptor Relocalization as well as Increased Beta-Adrenergic Receptor Numbers: Are These Changes Indications for Outcome?

    Article • Journal of Cardiac Surgery, July 2005, Wiley

    Dr. Louis Maximilian Buja

  196. Myocardial ischemia and reperfusion injury

    Article • Cardiovascular Pathology, July 2005, Elsevier

    Dr. Louis Maximilian Buja

  197. Alterations in Alpha Adrenoreceptor Density and Localization After Mechanical Left Ventricular Unloading With the Jarvik Flowmaker Left Ventricular Assist Device

    Article • The Journal of Heart and Lung Transplantation, May 2005, Elsevier

    Dr. Louis Maximilian Buja

  198. Fluorescence imaging microscopy of cellular markers in ischemic vs non-ischemic cardiomyopathy after left ventricular unloading

    Article • The Journal of Heart and Lung Transplantation, April 2005, Elsevier

    Dr. Louis Maximilian Buja

  199. Mechanical left ventricular unloading prior to reperfusion reduces infarct size in a canine infarction model

    Article • Catheterization and Cardiovascular Interventions, January 2005, Wiley

    Dr. Louis Maximilian Buja

  200. Expression of human β defensin 2 in thermal injury

    Article • Burns, November 2004, Elsevier

    Dr. Louis Maximilian Buja

  201. Effects of cytokines and heat shock on defensin levels of cultured keratinocytes

    Article • Burns, June 2004, Elsevier

    Dr. Louis Maximilian Buja

  202. Mathematical model to simulate the cellular dynamics of infection with human herpesvirus-6 in EBV-negative infectious mononucleosis

    Article • Journal of Medical Virology, October 2003, Wiley

    Dr. Louis Maximilian Buja

  203. Is inflammation the critical factor linking vulnerable coronary plaques to clinicalcoronary disease?

    Article • The American Journal of Medicine, May 2003, Elsevier

    Dr. Louis Maximilian Buja

  204. Localization of the transmembrane proteoglycan syndecan-4 and its regulatory kinases in costameres of rat cardiomyocytes: A deconvolution microscopic study

    Article • The Anatomical Record, August 2002, Wiley

    Dr. Louis Maximilian Buja

  205. Eosinophilic Pericarditis and Myocarditis

    Article • Circulation, June 2002, Wolters Kluwer Health

    Dr. Louis Maximilian Buja

  206. Sodium/hydrogen-exchanger inhibition during cardioplegic arrest and cardiopulmonary bypass: An experimental study

    Article • Journal of Thoracic and Cardiovascular Surgery, May 2002, Elsevier

    Dr. Louis Maximilian Buja

  207. Chronic Aortic Dissection not a Risk Factor for Neurologic Deficit in Thoracoabdominal Aortic Aneurysm Repair

    Article • European Journal of Vascular and Endovascular Surgery, March 2002, Elsevier

    Dr. Louis Maximilian Buja

  208. Calcium signaling mechanisms in dedifferentiated cardiac myocytes: comparison with neonatal andadult cardiomyocytes

    Article • Cell Calcium, December 2001, Elsevier

    Dr. Louis Maximilian Buja

  209. Esmolol and cardiopulmonary bypass during reperfusion reduce myocardial infarct size in dogs

    Article • The Annals of Thoracic Surgery, December 2001, Elsevier

    Dr. Louis Maximilian Buja

  210. Development of atherosclerotic plaque with endothelial disruption in Watanabe heritable hyperlipidemic rabbit aortas

    Article • Cardiovascular Pathology, January 2001, Elsevier

    Dr. Louis Maximilian Buja

  211. Amyloidosis as a cause of ischemic heart disease of small vessel origin

    Article • The American Journal of Medicine, August 2000, Elsevier

    Dr. Louis Maximilian Buja

  212. Palmitate-mediated Alterations in the Fatty Acid Metabolism of Rat Neonatal Cardiac Myocytes

    Article • Journal of Molecular and Cellular Cardiology, March 2000, Elsevier

    Dr. Louis Maximilian Buja

  213. Cytokines Increase Neonatal Cardiac Myocyte Calcium Concentrations: The Involvement of Nitric Oxide and Cyclic Nucleotides

    Article • Journal of Interferon & Cytokine Research, June 1999, Mary Ann Liebert Inc

    Dr. Louis Maximilian Buja

  214. Membrane Asymmetry in Isolated Canine Cardiac Sarcoplasmic Reticulum: Comparison with Skeletal Muscle Sarcoplasmic Reticulum

    Article • The Journal of Membrane Biology, July 1998, Springer Science + Business Media

    Dr. Louis Maximilian Buja

  215. Activation of the CytochromecGene by Electrical Stimulation in Neonatal Rat Cardiac Myocytes

    Article • Journal of Biological Chemistry, May 1998, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr. Louis Maximilian Buja

  216. Genomic DNA Sequence, Promoter Expression, and Chromosomal Mapping of Rat Muscle Carnitine Palmitoyltransferase I

    Article • Genomics, March 1998, Elsevier

    Dr. Louis Maximilian Buja

  217. Article • Molecular and Cellular Biochemistry, January 1998, Springer Science + Business Media

    Dr. Louis Maximilian Buja

  218. Electrical stimulation of neonatal cardiomyocytes results in the sequential activation of nuclear genes governing mitochondrial proliferation and differentiation

    Article • Proceedings of the National Academy of Sciences, October 1997, Proceedings of the National Academy of Sciences

    Dr. Louis Maximilian Buja

  219. Relationship of lipid alterations and impaired calcium homeostasis during myocardial ischemia

    Article • January 1997, Elsevier

    Dr. Louis Maximilian Buja

  220. Detection and localization of tumor necrosis factor-α in WHHL rabbit arteries

    Article • Atherosclerosis, August 1996, Elsevier

    Dr. Louis Maximilian Buja

  221. Improved Left Ventricular Function After Chronic Left Ventricular Unloading

    Article • The Annals of Thoracic Surgery, August 1996, Elsevier

    Dr. Louis Maximilian Buja

  222. Change in Expression of Heart Carnitine Palmitoyltransferase I Isoforms with Electrical Stimulation of Cultured Rat Neonatal Cardiac Myocytes

    Article • Journal of Biological Chemistry, May 1996, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr. Louis Maximilian Buja

  223. Acetyl Coenzyme A Carboxylase Activity in Neonatal Rat Cardiac Myocytes in Culture: Citrate Dependence and Effects of Hypoxia

    Article • Archives of Biochemistry and Biophysics, January 1996, Elsevier

    Dr. Louis Maximilian Buja

  224. Detection of iron-deficiency anemia in hospitalized patients by zinc protoporphyrin

    Article • Clinica Chimica Acta, January 1996, Elsevier

    Dr. Louis Maximilian Buja

  225. Hypoxia-induced Alterations in Cytoskeleton Coincide with Collagenase Expression in Cultured Neonatal Rat Cardiomyocytes,

    Article • Journal of Molecular and Cellular Cardiology, December 1995, Elsevier

    Dr. Louis Maximilian Buja

  226. Non-invasive management of coronary artery disease

    Article • The Lancet, September 1995, Elsevier

    Dr. Louis Maximilian Buja

  227. Apoptose und Zellproliferation bei HHV-6-Infektionen Regulationsmechanismen �ber p 53/bcl-2/ras-Interaktionen

    Article • Der Pathologe, March 1995, Springer Science + Business Media

    Dr. Louis Maximilian Buja

  228. Kinetic Properties of Carnitine Palmitoyltransferase I in Cultured Neonatal Rat Cardiac Myocytes

    Article • Archives of Biochemistry and Biophysics, August 1994, Elsevier

    Dr. Louis Maximilian Buja

  229. Cytoskeletal alterations in cultured cardiomyocytes following exposure to the lipid peroxidation product, 4-hydroxynonenal

    Article • Cell Motility and the Cytoskeleton, January 1994, Wiley

    Dr. Louis Maximilian Buja

  230. The role of ventricular wall stress in cardiac hypertrophy

    Article • Cardiovascular Pathology, January 1994, Elsevier

    Dr. Louis Maximilian Buja

  231. Thrombus and unstable angina

    Article • The Lancet, November 1993, Elsevier

    Dr. Louis Maximilian Buja

  232. Segmental systolic responses to brief ischemia and reperfusion in the hypertrophied canine left ventricle

    Article • Journal of the American College of Cardiology, October 1992, Elsevier

    Dr. Louis Maximilian Buja

  233. Role of thromboxane and serotonin as mediators in the development of spontaneous alterations in coronary blood flow and neointimal proliferation in canine models with chronic coronary artery stenoses and endothelial injury

    Article • Journal of the American College of Cardiology, May 1991, Elsevier

    Dr. Louis Maximilian Buja

  234. Effect of aspirin on local prostaglandin production and serotonin accumulation in a canine model with coronary cyclic flow variations or thrombosis

    Article • Journal of Molecular and Cellular Cardiology, April 1991, Elsevier

    Dr. Louis Maximilian Buja

  235. Method of removal of aortic endothelium affects arachidonic acid metabolism and vascular reactivity

    Article • European Journal of Pharmacology, February 1991, Elsevier

    Dr. Louis Maximilian Buja

  236. Regional cardiac adrenergic function using I-123 meta-iodobenzylguanidine tomographic imaging after acute myocardial infarction

    Article • The American Journal of Cardiology, February 1991, Elsevier

    Dr. Louis Maximilian Buja

  237. Lipid abnormalities in myocardial cell injury

    Article • Trends in Cardiovascular Medicine, January 1991, Elsevier

    Dr. Louis Maximilian Buja

  238. Role of new antiplatelet agents as adjunctive therapies in thrombolysis

    Article • The American Journal of Cardiology, January 1991, Elsevier

    Dr. Louis Maximilian Buja

  239. Potential usefulness of combined thromboxane A2 and serotonin receptor blockade for preventing the conversion from chronic to acute coronary artery disease syndromes

    Article • The American Journal of Cardiology, November 1990, Elsevier

    Dr. Louis Maximilian Buja

  240. Combined thromboxane A2synthetase inhibition and receptor blockade are effective in preventing spontaneous and epinephrine-induced canine coronary cyclic flow variations

    Article • Journal of the American College of Cardiology, September 1990, Elsevier

    Dr. Louis Maximilian Buja

  241. Free radicals alter ionic calcium levels and membrane phospholipids in cultured rat ventricular myocytes

    Article • Journal of Molecular and Cellular Cardiology, September 1990, Elsevier

    Dr. Louis Maximilian Buja

  242. Protection of the myocardium during myocardial infarction: Pharmacologic protection during thrombolytic therapy

    Article • The American Journal of Cardiology, May 1990, Elsevier

    Dr. Louis Maximilian Buja

  243. Differential enhancement of postischemic segmental systolic thickening by diltiazem

    Article • Journal of the American College of Cardiology, March 1990, Elsevier

    Dr. Louis Maximilian Buja

  244. Failure of nitroglycerin and diltiazem to reduce platelet-mediated vasoconstriction in dogs with coronary artery stenosis and endothelial injury: Further evidence for thromboxane A2 and serotonin as mediators of coronary artery vasoconstriction in vivo

    Article • Journal of the American College of Cardiology, March 1990, Elsevier

    Dr. Louis Maximilian Buja

  245. Assessment of myocardial systolic wall thickening using nuclear magnetic resonance imaging

    Article • Journal of the American College of Cardiology, September 1989, Elsevier

    Dr. Louis Maximilian Buja

  246. Diagnostic and prognostic utility of right-sided catheterization and endomyocardial biopsy in idiopathic dilated cardiomyopathy

    Article • The American Journal of Cardiology, April 1989, Elsevier

    Dr. Louis Maximilian Buja

  247. Serotonin S2and thromboxane A2-prostaglandin H2receptor blockade provide protection against epinephrine-induced cyclic flow variations in severely narrowed canine coronary arteries

    Article • Journal of the American College of Cardiology, March 1989, Elsevier

    Dr. Louis Maximilian Buja

  248. Altered calcium homeostasis in the pathogenesis of myocardial ischemic and hypoxic injury

    Article • Cell Calcium, October 1988, Elsevier

    Dr. Louis Maximilian Buja

  249. Gadolinium-DTPA-enhanced nuclear magnetic resonance imaging of reperfused myocardium: Identification of the myocardial bed at risk

    Article • Journal of the American College of Cardiology, October 1988, Elsevier

    Dr. Louis Maximilian Buja

  250. Iodine-123 phenylpentadecanoic acid and single photon emission computed tomography in identifying left ventricular regional metabolic abnormalities in patients with coronary heart disease: Comparison with thallium-201 myocardial tomography

    Article • Journal of the American College of Cardiology, July 1988, Elsevier

    Dr. Louis Maximilian Buja

  251. The role of coronary artery lesions in ischemic heart disease: Insights from recent clinicopathologic, coronary arteriographic, and experimental studies

    Article • Human Pathology, May 1987, Elsevier

    Dr. Louis Maximilian Buja

  252. Ancrod decreases the frequency of cyclic flow variations and causes thrombolysis following acute coronary thrombosis

    Article • American Heart Journal, April 1987, Elsevier

    Dr. Louis Maximilian Buja

  253. Detection and localization of recent myocardial infarction by magnetic resonance imaging

    Article • The American Journal of Cardiology, August 1986, Elsevier

    Dr. Louis Maximilian Buja

  254. Improved in vivo magnetic resonance imaging of acute myocardial infarction after intravenous paramagnetic contrast agent administration

    Article • The American Journal of Cardiology, April 1986, Elsevier

    Dr. Louis Maximilian Buja

  255. Propranolol in acute myocardial infarction: The MILIS experience

    Article • The American Journal of Cardiology, April 1986, Elsevier

    Dr. Louis Maximilian Buja

  256. Low density lipoprotein-receptor activity is lost in vivo in malignantly transformed renal tissue

    Article • FEBS Letters, February 1986, Wiley

    Dr. Louis Maximilian Buja

  257. Late thrombotic obstruction of aortic porcine bioprostheses

    Article • The American Journal of Cardiology, February 1986, Elsevier

    Dr. Louis Maximilian Buja

  258. Frequency-dependent myosin light chain phosphorylation in isolated myocardium

    Article • Journal of Molecular and Cellular Cardiology, January 1986, Elsevier

    Dr. Louis Maximilian Buja

  259. Early positive technetium-99m stannous pyrophosphate images as a marker of reperfusion after thrombolytic therapy for acute myocardial infarction

    Article • The American Journal of Cardiology, August 1985, Elsevier

    Dr. Louis Maximilian Buja

  260. Conversion from chronic to acute coronary artery disease: Speculation regarding mechanisms

    Article • The American Journal of Cardiology, December 1984, Elsevier

    Dr. Louis Maximilian Buja

  261. Measurement of myocardial infarct size by technetium pyrophosphate single-photon tomography

    Article • The American Journal of Cardiology, December 1984, Elsevier

    Dr. Louis Maximilian Buja

  262. Measurement of infarct size in acute canine myocardial infarction by single-photon emission computed tomography with technetium-99m pyrophosphate

    Article • The American Journal of Cardiology, July 1984, Elsevier

    Dr. Louis Maximilian Buja

  263. Effects of inotropic and chronotropic stimuli on acute myocardial ischemic injury

    Article • The American Journal of Cardiology, June 1984, Elsevier

    Dr. Louis Maximilian Buja

  264. Short- and long-term influence of beta-adrenergic antagonists after acute myocardial infarction

    Article • The American Journal of Cardiology, January 1984, Elsevier

    Dr. Louis Maximilian Buja

  265. Iodine-123 phenylpentadecanoic acid: Detection of acute myocardial infarction and injury in dogs using an iodinated fatty acid and single-photon emission tomography

    Article • The American Journal of Cardiology, December 1983, Elsevier

    Dr. Louis Maximilian Buja

  266. Fatty acylcarnitine accumulation and membrane injury in ischemic canine myocardium

    Article • The American Journal of Cardiology, October 1983, Elsevier

    Dr. Louis Maximilian Buja

  267. Editorial note Ventricular morphology as a prognostic indicator of outcome following cardiac surgery

    Article • International Journal of Cardiology, September 1983, Elsevier

    Dr. Louis Maximilian Buja

  268. Hydrogen peroxide contrast echocardiography

    Article • The American Journal of Cardiology, September 1983, Elsevier

    Dr. Louis Maximilian Buja

  269. Evaluation of hemostatic agents in experimental splenic lacerations

    Article • The American Journal of Surgery, February 1983, Elsevier

    Dr. Louis Maximilian Buja

  270. Myocardial rupture after myocardial infarction

    Article • The American Journal of Medicine, November 1982, Elsevier

    Dr. Louis Maximilian Buja

  271. "Doughnut" Technetium Pyrophosphate Myocardial Scintigrams

    Article • Clinical Nuclear Medicine, October 1982, Wolters Kluwer Health

    Dr. Louis Maximilian Buja

  272. Increased incidence and clinical correlation of persistently abnormal technetium pyrophosphate myocardial scintigrams following acute myocardial infarction in patients with diabetes mellitus

    Article • American Heart Journal, May 1982, Elsevier

    Dr. Louis Maximilian Buja

  273. Clinicopathologic correlates of acute ischemic heart disease syndromes

    Article • The American Journal of Cardiology, February 1981, Elsevier

    Dr. Louis Maximilian Buja

  274. Effect of chronic vitamin D deficiency on chick heart mitochondrial oxidative phosphorylation

    Article • Journal of Molecular and Cellular Cardiology, February 1981, Elsevier

    Dr. Louis Maximilian Buja

  275. Quantitation of experimental canine myocardial infarct size with technetium stannous pyrophosphate: A comparison of multipinhole and rotating slant hole emission tomography

    Article • The American Journal of Cardiology, February 1981, Elsevier

    Dr. Louis Maximilian Buja

  276. Cause and course of acute myocardial infarction

    Article • The American Journal of Medicine, December 1980, Elsevier

    Dr. Louis Maximilian Buja

  277. Localization of anti-mitochondrial antibody in experimental canine myocardial infarcts.

    Article • Proceedings of the National Academy of Sciences, November 1980, Proceedings of the National Academy of Sciences

    Dr. Louis Maximilian Buja

  278. Severe pulmonary hypertension associated with macronodular (postnecrotic) cirrhosis and autoimmune phenomena

    Article • The American Journal of Medicine, October 1980, Elsevier

    Dr. Louis Maximilian Buja

  279. Radionuclide evaluation of cardiac trauma

    Article • Seminars in Nuclear Medicine, April 1980, Elsevier

    Dr. Louis Maximilian Buja

  280. Radioimmunoassay of serum creatine kinase B isoenzyme in the diagnosis of acute myocardial infarction

    Article • The American Journal of Medicine, March 1980, Elsevier

    Dr. Louis Maximilian Buja

  281. Effect of glucose availability on functional membrane integrity, ultrastructure and contractile performance following hypoxia and reoxygenation in isolated feline cardiac muscle

    Article • Journal of Molecular and Cellular Cardiology, January 1980, Elsevier

    Dr. Louis Maximilian Buja

  282. Pathophysiologic considerations and clinicopathological correlates of technetium-99m stannous pyrophosphate myocardial scintigraphy

    Article • Seminars in Nuclear Medicine, January 1980, Elsevier

    Dr. Louis Maximilian Buja

  283. Dissecting aortic aneurysm involving a right-sided aortic arch

    Article • The American Journal of Cardiology, August 1979, Elsevier

    Dr. Louis Maximilian Buja

  284. Unstable angina pectoris: A randomized study of patients treated medically and surgically

    Article • The American Journal of Cardiology, June 1978, Elsevier

    Dr. Louis Maximilian Buja

  285. Is there a need for additional means of recognizing myocardial necrosis?

    Article • JAMA, October 1977, American Medical Association (AMA)

    Dr. Louis Maximilian Buja

  286. A relation between inhibition of protein synthesis and conformation of 5′-phosphorylated 7-methylguanosine derivatives

    Article • Journal of Molecular Biology, January 1977, Elsevier

    Dr. Louis Maximilian Buja

  287. Myocardial infarct imaging with technetium-99m phosphates

    Article • Seminars in Nuclear Medicine, January 1977, Elsevier

    Dr. Louis Maximilian Buja

  288. Cardiac pathologic findings in patients treated with bone marrow transplantation

    Article • Human Pathology, January 1976, Elsevier

    Dr. Louis Maximilian Buja

  289. Intranuclear glycogen deposits in human cardiac muscle cells: Ultrastructure and cytochemistry

    Article • Journal of Molecular and Cellular Cardiology, June 1975, Elsevier

    Dr. Louis Maximilian Buja

  290. Congestive heart failure and angina pectoris

    Article • The American Journal of Cardiology, December 1974, Elsevier

    Dr. Louis Maximilian Buja

  291. UNUSUAL NUCLEAR ALTERATIONS

    Article • The Lancet, March 1974, Elsevier

    Dr. Louis Maximilian Buja

  292. Cardiac ultrastructural changes induced by daunorubicin therapy

    Article • Cancer, October 1973, Wiley

    Dr. Louis Maximilian Buja

  293. Histaminase activity: A biochemical marker for medullary carcinoma of the thyroid

    Article • The American Journal of Medicine, December 1972, Elsevier

    Dr. Louis Maximilian Buja

  294. Occurrence of intramitochondrial glycogen in canine myocardium after prolonged anoxic cardiac arrest

    Article • Journal of Molecular and Cellular Cardiology, June 1972, Elsevier

    Dr. Louis Maximilian Buja

  295. The frequency and significance of coronary arterial thrombi and other observations in fatal acute myocardial infarction

    Article • The American Journal of Medicine, April 1972, Elsevier

    Dr. Louis Maximilian Buja

  296. Stenosis of the right pulmonary artery: A complication of acute dissecting aneurysm of the ascending aorta

    Article • American Heart Journal, January 1972, Elsevier

    Dr. Louis Maximilian Buja

  297. Iron in the heart

    Article • The American Journal of Medicine, August 1971, Elsevier

    Dr. Louis Maximilian Buja

  298. Pulmonary alveolar hemorrhage

    Article • The American Journal of Cardiology, February 1971, Elsevier

    Dr. Louis Maximilian Buja

  299. Amyloid coronary artery disease, primary systemic amyloidosis and paraproteinemia

    Article • Archives of Internal Medicine, October 1970, American Medical Association (AMA)

    Dr. Louis Maximilian Buja

  300. Clinically significant cardiac amyloidosis

    Article • The American Journal of Cardiology, October 1970, Elsevier

    Dr. Louis Maximilian Buja

  301. Pulmonary parenchymal ossific nodules in idiopathic hypertrophic subaortic stenosis

    Article • The American Journal of Cardiology, June 1970, Elsevier

    Dr. Louis Maximilian Buja